Fortress Biotech, Inc. FBIO
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -47.54%
- 1 year
- -25.29%
- Open
- 2.01
- Prev close
- 2.00
- Mkt cap
- 64.03M
- Vol
- 196.84K
- Avg vol
- 410.92K
- EPS
- 2.76
- P/E
- 0.70
- Div yield
- 0.00%
More statistics
- Low
- 1.89
- High
- 2.01
- Forward P/E
- -0.99
- Beta
- 1.75
- Short ratio
- 4.57
- Inst. own
- 15.78%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.83
- 200-d avg
- 1.84
- 1y target
- 14.33
5D chart
Signals (50)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 12:40 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:25 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:25 AM | 2 days ago |
| RSI: Oversold | Oct 30, 11:25 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:20 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:00 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:00 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:35 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 11:00 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:40 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 4 days ago |
| RSI: Oversold | Oct 28, 3:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:20 AM | 4 days ago |
| RSI: Overbought | Oct 28, 11:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:25 PM | 5 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:40 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:20 PM | 6 days ago |
| RSI: Oversold | Oct 26, 2:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:00 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:45 PM | 6 days ago |
News
3 weeks ago defenseworld.net
Johnson & Johnson (NYSE:JNJ) vs. Fortress Biotech (NASDAQ:FBIO) Head to Head Review
Fortress Biotech (NASDAQ: FBIO - Get Free Report) and Johnson and Johnson (NYSE: JNJ - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two…
1 month ago defenseworld.net
Contrasting RYTHM (NASDAQ:RYM) and Fortress Biotech (NASDAQ:FBIO)
RYTHM (NASDAQ: RYM - Get Free Report) and Fortress Biotech (NASDAQ: FBIO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two…
1 month ago globenewswire.com
Journey Medical Corporation to Participate in September 2026 Investor Conferences
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and…
1 month ago globenewswire.com
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
2 months ago globenewswire.com
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130…
2 months ago seekingalpha.com
Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript
Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript
2 months ago prnewswire.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)
NEW YORK, Aug. 7, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Fortress Biotech, Inc. (NASDAQ: FBIO) concerning possible breaches of fiduciary duties. If…
2 months ago globenewswire.com
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
-
3 months ago benzinga.com
Fortress Biotech’s Urica Therapeutics Says Crystalys Closes Oversubscribed $130M Series B Financing To Support Late-Stage Global Clinical Development And Commercialization Preparation For Dotinurad
Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in
3 months ago globenewswire.com
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing
MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys…
3 months ago seekingalpha.com
Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy
Fortress Biotech is trading below its cash balance, offering deep value relative to its assets and recent financial improvements. FBIO's Q1 2026 saw a dramatic cash increase to $255.8M and net profit…
5 months ago seekingalpha.com
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. FBIO's recent windfall from the Menkes disease drug sale positions it to easily…
5 months ago globenewswire.com
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on…
5 months ago globenewswire.com
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
-
5 months ago benzinga.com
Fortress Biotech Q1 EPS $2.82 Beats $(0.22) Estimate, Sales $16.038M Miss $16.338M Estimate
Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $2.82 per share which beat the analyst consensus estimate of $(0.22) by 1381.82 percent. This is a 687.5 percent increase over losses of…
5 months ago globenewswire.com
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205…
5 months ago globenewswire.com
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position…
5 months ago globenewswire.com
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a…
6 months ago globenewswire.com
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
6 months ago globenewswire.com
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100…
-
7 months ago benzinga.com
Fortress Biotech Q4 EPS $(0.30) Beats $(0.42) Estimate, Sales $16.079M Miss $21.018M Estimate
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.42) by 28.57 percent. This is a 15.38 percent decrease over losses of…
7 months ago globenewswire.com
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205…
-
7 months ago benzinga.com
Fortress Biotech And Cyprium Therapeutics Announce The Closing Of The Sale Of Cyprium's Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $205M
Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing of the sale of Cyprium's Rare Pediatric…
-
8 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $17 price target.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago benzinga.com
Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket
Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket
1 year ago benzinga.com
Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
2 years ago benzinga.com
Around $10M Bet On This Tech & Telecom Stock? Check Out These 3 Stocks Insiders Are Buying
Around $10M Bet On This Tech & Telecom Stock? Check Out These 3 Stocks Insiders Are Buying
-
2 years ago benzinga.com
Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Fisker Inc. (NYSE: FSR) rose sharply during Friday’s session after the company provided a December 2023 business update.
-
2 years ago benzinga.com
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday saw 132 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 99 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Pancreatic Cancer Action Network Urges Advocates From All 50 States To Call On Congress To Increase Federal Funding For Pancreatic Cancer Research
Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June 14, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer…
-
3 years ago benzinga.com
Earnings Scheduled For May 26, 2023
Companies Reporting Before The Bell • LightInTheBox Holding (NYSE:LITB) is estimated to report earnings for its first quarter.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 258 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
OnFriday, 143 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 446 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 101 companies made new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 466 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 729 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 524 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows.